53
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      eCAM benefits from diversity that derives from CAM

      editorial
      Evidence-based Complementary and Alternative Medicine
      Oxford University Press

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          ‘Diversity’ is now a magic word, showing up everywhere and often used to embrace many aspects of human activity, whether in government, the arts, sciences, research, choice of research subjects or so on. In many respects diversity represents an encompassing teamwork, and we all know the success of teams in sports in popular terms and the rewards of successful research teams. Thus, we can safely conclude that a diverse team can be a creative team since when investigators of different points of view are brought together, they ponder and question the interpretations, procedures and practices of others. Such is the case for the scientific approach (1). Thus, often butting heads, sometimes even locking horns in healthy debate, is most often resolved by the emergence of creativity. I will now propose several ways in which eCAM approaches the question of diversity and I hope that in the process we also engage in this act of creation. First, the editorial board of eCAM is one that is diverse, and to ensure one aspect of creativity, many of us have never worked together, thus allowing for the infusion of different points of view. Our first purpose in establishing the eCAM editorial board has been to gather a mixture of experienced biomedical scientists and to combine them with newcomers from a variety of fields who are willing to embrace CAM and to extend themselves beyond their better known academic classifications or ‘pigeonholes’. As one of our bases is in Japan, our search for diversity began in Asia at biomedical conferences and research centers in Japan, Taiwan, Korea, India, China, Hong Kong and Thailand, at the same time visiting similar events and places in Mexico, Venezuela, Brazil, Europe and the United States. And these journeys were just the beginning; we are now in the planning stages for increased involvement in South America, the Middle East and the African continent. In our official letter inviting scholars to join our board, we include the following words: ‘CAM is a worldwide phenomenon and eCAM will seek to be inclusive of new and old work all over the globe. With this same broad view, we envision an active and varied Editorial Board on which philosophers and historians will be engaged in dialogues with neuroscientists, immunologists, practitioners and clinicians.’ To date, the editorial board numbers about 75 members, who reside in most of the continents and many countries. What are most important are not so much the numbers as the disciplines that they embrace, and the list is ever extending into new and exciting areas of CAM. Clearly the crucial functions of editorial board members are threefold: submitting their own manuscripts, critically reviewing papers and recruiting papers. Their voices as contributors and referees have been critical in establishing the unique worldview that can be found in each issue of eCAM. As one peruses our disciplines there is, to be sure, a seeming focus on immunology—but not to the exclusion of other disciplines. Thus, the triangle of the three regulatory systems (nervous–endocrine–immune) is not so evenly distributed, but at least the immunologists realize the intimate connectedness of this triumvirate. Going beyond one's usual classification is best exemplified by invertebrate immunologists (2,3), who bring fresh notions of using animal products as prime targets from which newer technologies can be applied to CAM. Molecular approaches based upon antimicrobial peptides promise to add to the emerging bioprospecting compendium, moving it from the realm of invertebrate immunology to the CAM sector (4–6). (There was already a historical precedent for using products from snails (7).) Moving to the apiary, biologists who look at products from honeybees are already known internationally (8–12). The lesson to be learned and eventually put into practice concerns a wider approach to a search for useful drugs and applicable CAM products from diverse terrestrial and marine sources (13–16). There is even room to consider a diverse array of complex derivatives from certain vertebrates such as snakes (17). Botanists (qua ethnobotanists, herbalists) have already made their mark, especially as they literally dig up more mushrooms and cultivate diverse plants (11,12,18–23). Second, the other essential ingredient for successful eCAM diversity is the inclusion of experienced, recognized biomedical scientists who are bona fide members of the CAM community and who are open to embracing somewhat tangential approaches that prescience reveals will be fruitful paths to follow. These two tracks—especially this second—should guard against the rather natural tendency of people of like kind (educational background, use of similar techniques etc.) to want to work with their long-term colleagues, i.e. people with whom they have associated before or have often been seen at meetings. Couple these two strategies with an emphasis on the inclusion of newer technologies with the insistence on evidence and we have designed a formula that should remove some of the shroud around CAM, thus giving it a greater measure of acceptance within the western medical community and even the CAM community itself. All eCAM is doing is redirecting biomedical scientists well known in one discipline into thinking about the utility of their work and its applicability to another discipline. In my view, this is the creative thought and work that is needed to bring CAM into the arena of western medicine. Third, of course, recognizing and emphasizing diversity seems only natural since the very discipline of CAM is itself diverse, complex and controversial. It includes such diverse disciplines as osteopathy, homeopathy, chiropractic, acupuncture, herbal medicine, energy medicine and meditation, which are associated with the ancient approaches of China, India, Japan and Korea. Clearly other ancient cultures have much to offer and will, we hope, be uncovered as we delve deeper into practices in other parts of the world, such as Latin America, the Middle East, North America and the south Pacific, that have not been so popularized. Some of the latter, less publicized ways of doing things from these regions could well coincide with those from ancient Asia, differing only as a result of the available natural products. In other words, plants or animal products may differ but offer similar remedies for similar health problems. Thus, remedies may to some extent be intertwined culturally and geographically. In every instance barring cultural and geographical lumping together, all have been concerned with improving the quality of life. Finally, despite these examples of diversity in numbers, geographical origins and disciplines and scientific approach, there is the difficulty of reconciling the very nature of CAM with certain realities, i.e. the palpable need to undergird CAM with evidence-based results that can, through rigor, occupy the pinnacle of the experimental triangle devoted to immunological benefits as proposed by Goldrosen and Strauss (24). For, as has been pointed out in previous editorials, there is a need for rigorous science if CAM and indeed eCAM are to be taken more seriously, thus ensuring less skepticism from its adherents and disciples and also from the traditional medical establishment and pharmaceutical industry. Now and in the near future, eCAM is discussing ways to consider seriously case reports, not the ideal within an acceptable scientific context. An excellent example devoted to Alzheimer's disease has led the way (25).

          Related collections

          Most cited references26

          • Record: found
          • Abstract: not found
          • Article: not found

          Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

          Amyloid-beta peptide (Abeta) has a key role in the pathogenesis of Alzheimer disease (AD). Immunization with Abeta in a transgenic mouse model of AD reduces both age-related accumulation of Abeta in the brain and associated cognitive impairment. Here we present the first analysis of human neuropathology after immunization with Abeta (AN-1792). Comparison with unimmunized cases of AD (n = 7) revealed the following unusual features in the immunized case, despite diagnostic neuropathological features of AD: (i) there were extensive areas of neocortex with very few Abeta plaques; (ii) those areas of cortex that were devoid of Abeta plaques contained densities of tangles, neuropil threads and cerebral amyloid angiopathy (CAA) similar to unimmunized AD, but lacked plaque-associated dystrophic neurites and astrocyte clusters; (iii) in some regions devoid of plaques, Abeta-immunoreactivity was associated with microglia; (iv) T-lymphocyte meningoencephalitis was present; and (v) cerebral white matter showed infiltration by macrophages. Findings (i)-(iii) strongly resemble the changes seen after Abeta immunotherapy in mouse models of AD and suggest that the immune response generated against the peptide elicited clearance of Abeta plaques in this patient. The T-lymphocyte meningoencephalitis is likely to correspond to the side effect seen in some other patients who received AN-1792 (refs. 7-9).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Drugs from the deep: marine natural products as drug candidates.

            In recent years, marine natural product bioprospecting has yielded a considerable number of drug candidates. Most of these molecules are still in preclinical or early clinical development but some are already on the market, such as cytarabine, or are predicted to be approved soon, such as ET743 (Yondelis). Research into the ecology of marine natural products has shown that many of these compounds function as chemical weapons and have evolved into highly potent inhibitors of physiological processes in the prey, predators or competitors of the marine organisms that use them. Some of the natural products isolated from marine invertebrates have been shown to be, or are suspected to be, of microbial origin and this is now thought to be the case for the majority of such molecules. Marine microorganisms, whose immense genetic and biochemical diversity is only beginning to be appreciated, look likely to become a rich source of novel chemical entities for the discovery of more effective drugs.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recent trends and important developments in propolis research

              The newest developments in propolis pharmacological research are summarized. The problem regarding biological studies, caused by the chemical variability of propolis, is discussed. The most important trends and developments in recent propolis research are outlined: biological studies performed with chemically characterized samples, bioassay-guided studies of active principles and comparative biological studies of propolis of different origin and chemical composition. These types of studies are extremely valuable with respect to propolis standardization and practical applications in therapy. They will allow scientists to connect a particular chemical propolis type to a specific type of biological activity and formulate recommendations for practitioners.
                Bookmark

                Author and article information

                Journal
                Evid Based Complement Alternat Med
                Evidence-based Complementary and Alternative Medicine
                Evidence-based Complementary and Alternative Medicine
                Oxford University Press
                1741-427X
                1741-4288
                September 2005
                : 2
                : 3
                : 263-265
                Affiliations
                Laboratory of Comparative Neuroimmunology, Department of Neurobiology, David Geffen School of Medicine, University of California Los Angeles, CA 90095-1763, USA
                Author notes
                For reprints and all correspondence: Edwin L. Cooper, Distinguished Professor, Laboratory of Comparative Neuroimmunology, Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1763, USA. Tel: +1-310-825-9567; Fax: +1-310-825-2224; E-mail: ecam@ 123456mednet.ucla.edu
                Article
                10.1093/ecam/neh120
                1193560
                16136204
                c72549d6-9904-40f7-9f85-f04966bfa291
                © The Author (2005). Published by Oxford University Press. All rights reserved.

                The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@ 123456oupjournals.org

                History
                Categories
                Editorial

                Complementary & Alternative medicine
                Complementary & Alternative medicine

                Comments

                Comment on this article